Caricamento...
Activation of antigen-exposed iMC-DCs at the “right place” and “right time” promotes potent anti-tumor immunity
To better control the “licensing” of pro-Th1 dendritic cells (DCs), Spencer and colleagues have developed a synthetic ligand-inducible chimeric receptor, iMyD88/CD40 (iMC), incorporating synergistic Toll-like receptor (TLR) and costimulatory signaling elements, permitting DC regulation in vivo withi...
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Landes Bioscience
2012
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3382847/ https://ncbi.nlm.nih.gov/pubmed/22737615 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.18482 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|